Moleculin Biotech Inc

MOL

Company Profile

  • Business description

    Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

  • Contact

    5300 Memorial Drive
    Suite 950
    HoustonTX77007
    USA

    T: +1 713 300-5160

    E: [email protected]

    https://www.moleculin.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    17

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,723.5017.90-0.20%
CAC 407,589.6636.210.48%
DAX 4023,350.55293.171.27%
Dow JONES (US)42,206.8235.160.08%
FTSE 1008,774.6517.15-0.20%
HKSE23,530.48292.741.26%
NASDAQ19,447.4198.86-0.51%
Nikkei 22538,403.2385.11-0.22%
NZX 50 Index12,569.0558.27-0.46%
S&P 5005,967.8413.03-0.22%
S&P/ASX 2008,505.5018.20-0.21%
SSE Composite Index3,359.902.21-0.07%

Market Movers